Guest Speaker: Scott Urquhart, PA-C, DFAAPA, Diabetes and Thyroid Associates Spotsylvania, VA
Learn the latest evidence surrounding the use of CGM in people with T2D not on intensive insulin therapy. We will review the AACE guidelines and uncover how you can start using CGM in this population
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G6 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.
Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.
Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.
The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older.
Scott Urquhart is a paid spokesperson for Dexcom. Dr. Urquhart is a guest on this episode of the podcast.
Dexcom G6 is covered for 3 out of 4 patients with T2D on mealtime insulin with commercial health insurance plans.*
Dexcom Follow app: The Dexcom G6 App allows you to share your glucose data with up to 10 people. By downloading the Dexcom Follow App, followers can view your glucose data directly from their smart devicewhether they live down the street or across the country. Separate Follow App required. For a list of compatible devices, visit www.dexcom.com/compatibility.
Connectivity – basics (https://provider.dexcom.com/dexcom-cgm/collaborators)
Time in Range: Recommendations from the International Consensus on Time in Range, 2019 recommend individualized glycemic targets for high risk and/or older adults with a focus on reducing the percentage of time spent less than 70 md/dL and preventing excessive hyperglycemia. Everyone’s treatment plan is different, talk to your healthcare provider before changing your Time in Range settings.
Brief Safety Statement
Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
The web-based Dexcom CLARITY software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.
Dexcom, Dexcom Follow, Dexcom CLARITY, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.
- Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections:The DIAMOND Randomized Clinical Trial. 2017;317(4):371–378. doi:10.1001/jama.2016.19975
- William H. Polonsky, Danielle Hessler, Katrina J. Ruedy, Roy W. Beck; for the DIAMOND Study Group, The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial.Diabetes Care 1 June 2017; 40 (6): 736–741. https://doi.org/10.2337/dc17-0133
- Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin:A Randomized Clinical Trial. 2021;325(22):2262–2272. doi:10.1001/jama.2021.7444
- William H. Polonsky, PhD,1,2 Emily C. Soriano, PhD,3 and Addie L. Fortmann, PhD3 The Role of Retrospective Data Review in the Personal Use of Real-Time Continuous Glucose Monitoring: Perceived Impact on Quality of Life and Health Outcomes
- Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther 2019;21:81–85.